Dr. Raymond A. Huml is Executive Director, Global Strategic Drug Development at Quintiles and head of Quintiles Global Biosimilars Strategic Planning. In this capacity, he works with Quintiles strategic and operational experts to provide an end-to-end biosimilars solution to the biopharmaceutical industry.
Dr. Huml has more than 25 years of work experience in the healthcare industry, including the last 16 years at Quintiles working in the areas of medical writing, regulatory affairs, corporate development, and clinical drug development. He formerly led the Global Due Diligence group in Quintiles Corporate Development. He has been involved in all major risk-based transactions providing project management and underwriting expertise to over 200 due diligence teams - including deals that involved biosimilar products and portfolios of biosimilar products - that resulted in over $2.9b in capital committed to partnerships of all sizes.
Dr. Huml has published over 50 articles and two books on the pharmaceutical industry: one on due diligence and one on competitive intelligence.
Dr. Huml earned his Doctor of Veterinary Medicine at North Carolina State University and his Master of Science in Biology at East Stroudsburg University. He earned his US Regulatory Affairs Certification from the Regulatory Affairs Professionals Society.